Posts

4P-Pharma will attend the 10th DDIP, November 28th-29th 2019 – Barcelona, Spain

We’re glad to announce that Céline Martin, 4P-Pharma’s R&D Manager will speak during  the 10th Drug Discovery Innovation Programme (10th DDIP) organized by the World BI, November 28th-29th 2019, at Barcelona, Spain: “Pharmaceutical Development Through A Rapid Value Creation Business Model”.

To learn more about 4P-Pharma, our pipeline and our partnerships, please feel free to contact Céline or Roselina Lam, our Business Developer, via email.

4P-Pharma an actor in ADHD pipeline drug development

4P-Pharma is a recognized actor in the ADHD pipeline drug development.

Stimulant abuse and addiction is a major global health problem and prescription drugs are indeed more and more abused, in virtue of their “rewarding” psychotropic effects.  ADHD medications abuse increased by 4 fold, and led to a 400% increased in emergency room visits from 2006 to 2014.  4P-003 is our innovative product developed as a novel deterrent approach for stimulant misuse, under a 505(b)2 approval.

https://www.businesswire.com/news/home/20170821005375/en/Attention-Deficit-Hyperactivity-Disorder-ADHD—Pipeline